Tirzepatide arrived in clinical practice with a mechanism that differs in a meaningful way from semaglutide, and the trial results reflect that difference. At the same time, comparing the two drugs directly requires care: SURMOUNT and STEP were not head-to-head trials, they enrolled somewhat different populations, and the weight loss figures most widely cited represent mean outcomes that obscure significant individual variation. What follows is an attempt to present the evidence as precisely as it exists, without either oversimplifying the numbers or overstating their clinical implications.
Mechanism: Why the Drugs Are Different
Semaglutide is a GLP-1 receptor agonist. It activates the glucagon-like peptide-1 receptor, which reduces appetite, slows gastric emptying, and modulates insulin and glucagon secretion. This mechanism is well-characterized across more than a decade of clinical use.
Tirzepatide is a dual agonist: it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP was historically considered less therapeutically relevant than GLP-1, and its role in weight regulation was not well understood until recently. The clinical data from tirzepatide trials has substantially revised that understanding. GIP receptor activation appears to amplify the metabolic effects of GLP-1 agonism through mechanisms that are still being characterized, including effects on adipose tissue and insulin sensitivity.
This dual mechanism is the pharmacological basis for the observed efficacy difference between the two drugs at comparable stages of treatment. Whether it also accounts for any difference in tolerability is less clear from current data.
SURMOUNT-1 and STEP-1: The Core Trial Data
The primary evidence for each drug in the weight-management indication comes from separate trial programs. SURMOUNT-1 evaluated tirzepatide (5 mg, 10 mg, and 15 mg doses) in adults with obesity or overweight plus at least one weight-related comorbidity, but without type 2 diabetes. STEP-1 evaluated semaglutide 2.4 mg in a similar population. Both trials ran for 72 weeks and used lifestyle intervention as the common background treatment.
Primary efficacy outcomes at 72 weeks
- Tirzepatide 15 mg (SURMOUNT-1): mean weight loss 22.5%; 57% of participants lost ≥20% of body weight
- Tirzepatide 10 mg (SURMOUNT-1): mean weight loss 21.4%
- Tirzepatide 5 mg (SURMOUNT-1): mean weight loss 16.0%
- Semaglutide 2.4 mg (STEP-1): mean weight loss 14.9%; 35% of participants lost ≥20% of body weight
- Placebo (both trials): mean weight loss 2.4–2.6%
The headline difference—22.5% vs 14.9%—is clinically meaningful. A 7.6 percentage point difference in mean weight loss, sustained over 72 weeks in a rigorous randomized trial, represents a genuine pharmacological distinction rather than noise. The proportion of patients achieving ≥20% weight loss (57% vs 35%) reinforces this.
What the means conceal
Mean outcomes mask the distribution of individual responses. In both trials, a substantial minority of participants lost significantly more or less than the mean. In SURMOUNT-1, approximately 18% of participants on tirzepatide 15 mg lost 30% or more of body weight—an outcome that was not achievable with any prior pharmacotherapy. At the same time, non-responders (defined as less than 5% weight loss at 72 weeks) were present in both treatment arms.
This variability is clinically important because it means that the expected outcome for any individual patient cannot be reliably predicted from population means. A patient who responds to semaglutide well may reach outcomes equivalent to or better than the tirzepatide mean. Conversely, a non-responder on semaglutide may also be a non-responder on tirzepatide, since the mechanisms, while distinct, likely share downstream pathways.
Head-to-Head Comparison: The SURPASS-CVOT and SURMOUNT-5 Data
The comparison most clinicians and patients want—a direct randomized trial of tirzepatide versus semaglutide in the same population at equivalent doses—now exists in a form. SURMOUNT-5, published in early 2025, randomized adults with obesity to tirzepatide (maximum tolerated dose up to 15 mg) or semaglutide (maximum tolerated dose up to 2.4 mg) for 72 weeks.
The results confirmed the pattern seen in the independent trials: tirzepatide produced greater mean weight loss than semaglutide in the same population under the same conditions. The primary endpoint difference was approximately 7–8 percentage points, consistent with the earlier cross-trial comparisons. Tirzepatide was not uniformly superior in all secondary endpoints, and the tolerability profiles were broadly similar, with both drugs producing mainly gastrointestinal side effects during dose escalation.
Which drug is accessible in your state and through which programs depends on your clinical profile and budget.
See Available Options →Safety and Tolerability: Where the Drugs Converge
The side effect profiles of tirzepatide and semaglutide are qualitatively similar. Both primarily cause gastrointestinal effects during dose escalation: nausea, vomiting, diarrhea, and constipation. Both require gradual dose escalation protocols to minimize these effects. Discontinuation due to adverse events occurred at rates of approximately 4–7% in both SURMOUNT and STEP trial arms.
| Side Effect | Tirzepatide (SURMOUNT-1) | Semaglutide (STEP-1) |
|---|---|---|
| Nausea | ~32% (any grade) | ~44% (any grade) |
| Diarrhea | ~23% | ~32% |
| Vomiting | ~12% | ~25% |
| Constipation | ~17% | ~24% |
| Discontinuation (AEs) | ~4.3% | ~4.5% |
The numerically lower rates of gastrointestinal side effects with tirzepatide relative to semaglutide in the SURMOUNT vs STEP comparison may reflect differences in dose escalation schedules, trial population characteristics, or the GIP component’s modulating effects—the mechanism is not yet fully established. In the direct SURMOUNT-5 comparison, gastrointestinal event rates were more similar.
Contraindications are similar for both drugs. A personal or family history of medullary thyroid carcinoma, or a diagnosis of Multiple Endocrine Neoplasia syndrome type 2 (MEN2), is a contraindication for both. Pancreatitis history requires careful risk assessment. Both drugs should be used with caution in patients with severe gastrointestinal conditions, and neither is approved for use in pregnancy.
Access, Cost, and the Practical Comparison
Efficacy data is only one dimension of the decision. For many patients, access and cost are more immediately determinative.
Semaglutide (as Wegovy) has a longer market history, broader insurance formulary inclusion in plans that do cover obesity medications, and wider availability through telehealth platforms including compounded formulations. Tirzepatide (as Zepbound) has been available since late 2023 and has expanded rapidly, but compounded tirzepatide availability is more variable and the regulatory environment around it has been more contested.
Retail list prices are similar: both Wegovy and Zepbound are priced above $1,000 per month without coverage. For patients accessing either drug through telehealth cash-pay programs, tirzepatide-based programs tend to be slightly more expensive than semaglutide-based programs, though this varies considerably by provider and formulation type.
Important: Neither drug should be selected based on efficacy data alone. The choice between tirzepatide and semaglutide involves clinical factors including comorbidities, prior medication history, tolerability, access, and cost—all of which require evaluation by a licensed physician familiar with the individual patient’s history. Population-level trial outcomes are not predictive of individual response.
What Clinicians Consider in Practice
In clinical practice, the choice between tirzepatide and semaglutide is rarely a simple efficacy optimization. Physicians typically consider:
- Whether the patient has previously tried and failed on semaglutide, which is a specific clinical indication for considering tirzepatide
- The patient’s tolerance of gastrointestinal side effects at prior escalation steps
- Insurance formulary: many plans cover one but not the other, making the covered drug the first-line choice regardless of comparative efficacy
- The presence of type 2 diabetes, which may favor one drug’s diabetes-indication dosing over the obesity-indication dosing under certain plan coverage structures
- Cost and availability of compounded formulations in the patient’s state
The right drug depends on more than the trial data
Patients who want to understand which GLP-1 medications are available through licensed physicians in their state—and at what cost—may find a structured comparison useful before their clinical consultation.
Compare Available Programs →Sources & References
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM, 2022.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). NEJM, 2021.
- Wadden TA et al. 2.4 mg Semaglutide in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP-2). NEJM, 2021.
- Aronne LJ et al. Tirzepatide vs Semaglutide in Adults with Obesity (SURMOUNT-5). NEJM, 2025.
- Lilly. SURMOUNT-1 full trial data and supplementary appendix. ClinicalTrials.gov NCT04184622.
- Drucker DJ. The biology of GIP and GIP receptor agonists and their potential implications for therapy. Nat Rev Endocrinol, 2022.
Medical disclaimer: This article presents clinical trial data for educational purposes and does not constitute medical advice. The choice between GLP-1 medications requires evaluation by a licensed physician who can assess individual clinical factors. Individual responses to these medications vary substantially from population mean outcomes. DawaMed is not a medical provider and does not prescribe medications.
Looking further ahead: retatrutide — a triple agonist targeting GLP-1, GIP, and glucagon — showed 24% average weight loss in Phase 2 trials, potentially surpassing both semaglutide and tirzepatide when it reaches approval.